Company Overview
Company Type: Private Company
Website: www.entospharma.com
Number of Employees: 24
Year Founded: 2011
Total Amount Raised (CAD mm)†: 0.13
Total Rounds of Funding**:2
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Entos Pharmaceuticals Inc., a biotechnology company, develops nucleic acid-based therapies using a drug delivery platform. It offers therapies for the treatment of oncology, autoimmune, and age-related diseases. Entos Pharmaceuticals Inc. has research and collaboration with Eli Lilly and Company. The company was incorporated in 2011 and is based in Edmonton, Canada with additional offices in London, United Kingdom and San Diego, California.


Financial Information (Currency: CAD, in mm)
Total Revenue
 8.3
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
 24
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Lewis, John D.
Founder & CEO
Duncan, Roy 
Founder & Member of Advisory Board
Zijlstra, Andries 
Founder & Director
Raturi, Arun 
Chief Scientific Officer
Chen, Steve 
Chief Medical Officer
Ding, Jason 
Chief Business Officer

Key Board Members
Name
Title
Duncan, Roy 
Founder & Member of Advisory Board
Zijlstra, Andries 
Founder & Director


Primary Industry Classification
Biotechnology


Primary Office Location
10230 Jasper Avenue Unit 4550 | Edmonton, AB | T5J 4P6 | Canada
Phone: 800-727-0884   

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Eli Lilly and Company (NYSE:LLY)
Jan-06-2022
Unknown
-
Growth


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jan-06-2022
Jan-06-2022
Private Placement
Target
Entos Pharmaceuticals Inc.
Eli Lilly and Company (NYSE:LLY)

-
May-11-2020
May-26-2020
Private Placement
Target
Entos Pharmaceuticals Inc.


0.10
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jun-07-2023
Client Announcements
Aegis Life Awards Grant to Develop DNA-Encoded Antibodies Against Infectious Diseases
Apr-25-2023
Company Conference Presentations
Entos Pharmaceuticals Inc. Presents at 2023 Bloom Burton & Co. Healthcare Investor Conference, Apr-25-2023 02:30 PM
Apr-18-2023
Company Conference Presentations
Entos Pharmaceuticals Inc. Presents at 2nd LNP Formulation & Process Development Summit, Apr-18-2023 02:30 PM
Jan-09-2023
Company Conference Presentations
Entos Pharmaceuticals Inc. Presents at BIO Partnering at JPM 2023, Jan-09-2023
Sep-29-2022
Product-Related Announcements
Entos Pharmaceuticals Passes Significant Enrollment Milestone in Phase 2 Clinical Trial of its COVID-19 DNA Vaccine


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
Infinata, Inc.
Infinata Research
Nov 11, 2020 03:35 AM
Entos Pharmaceuticals Inc.
Entos Pharmaceutical Inc - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Sep 08, 2020 10:01 AM
Entos Pharmaceuticals Inc.
Entos Pharmaceutical Inc - Company Report
Reports
9
Infinata, Inc.
Infinata Research
Jun 10, 2020 09:11 AM
Entos Pharmaceuticals Inc.
Entos Pharmaceutical Inc - Company Report
Reports
9
Infinata, Inc.
Infinata Research
Mar 11, 2020 04:25 AM
Entos Pharmaceuticals Inc.
Entos Pharmaceutical Inc - Company Report
Reports
9
Infinata, Inc.
Infinata Research
Dec 16, 2019 05:40 AM
Entos Pharmaceuticals Inc.
Entos Pharmaceutical Inc - Company Report
Reports
9
Infinata, Inc.
Infinata Research
Sep 30, 2019 05:41 AM
Entos Pharmaceuticals Inc.
Entos Pharmaceutical Inc - Company Report
Reports
9
Infinata, Inc.
Infinata Research
Jun 10, 2019 06:45 AM
Entos Pharmaceuticals Inc.
Entos Pharmaceutical Inc - Company Report
Reports
9
Infinata, Inc.
Infinata Research
Mar 11, 2019 04:51 AM
Entos Pharmaceuticals Inc.
Entos Pharmaceutical Inc - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Dec 17, 2018 05:43 AM
Entos Pharmaceuticals Inc.
Entos Pharmaceutical Inc - Company Report
Reports
8


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.


Recent Major Filings

Key Filings
Filed On
Company Name
Source
Form Type
Size
Jul-15-2019
ImmunoPrecise Antibodies Ltd. (NasdaqGM:IPA)
SEDAR
News Releases
37 KB

Key Board Members Details
Name
Title
Phone
Fax
Email
Duncan, Roy 
Founder & Member of Advisory Board
800-727-0884
-

Zijlstra, Andries 
Founder & Director
800-727-0884
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Lewis, John D.
Founder & CEO
(780) 862-7445
-
john.lewis@entospharma.com
Duncan, Roy 
Founder & Member of Advisory Board
800-727-0884
-

Zijlstra, Andries 
Founder & Director
800-727-0884
-

Raturi, Arun 
Chief Scientific Officer
800-727-0884
-

Chen, Steve 
Chief Medical Officer
(858) 412-6148
-

Ding, Jason 
Chief Business Officer
800-727-0884
-

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
